Page 8 - Efficacy Data News Today

>> when will children under 12 be able to get vaccinated? >> soon, i believe. soon in the sense that i do not tell any scientist what they should do. i do not interfere. [ applause ] and so, they are doing -- they are doing the examinations now, the testing now, and making the decision now. >> sanjay, what are your thoughts on that? >> i have been following this very closely and talking to the scientists involved with these trials. i think its going to break down into three age groups. 5 to 11, ...

Analysis: Vaccinated people should mostly feel safe being in public without masks Dr. Dora Anne Mills explains why she is more confident about not masking and when she may feel a need to put one on. By Dr. Dora Anne MillsMaineHealth Read Article It’s been a very hectic and wonderful couple of weeks, with our MaineHealth teams vaccinating in dozens of middle and high schools. In only the first week since most in this age group have been eligible, 35% of those 12 – 18 years old in Maine ha...

Covis Pharma Group COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo-Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide) COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo-Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide) ZUG, Switzerland, April 15, 2021 (GLOBE NEWSWIRE) -- Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutio...

Here? will there be votes, will there be movement on this? >> reporter: david, the reality here, this faces a massive uphill challenge in the senate. majority leader chuck schumer says hes committed to bringing both bills to the floor, but the bottom line here, democrats just dont have the votes to get it passed. they need the support of at least ten republicans. so, tonight, the white house is eyeing ways to be able to address gun violence through executive action, but any major reform is going...

Efficacy data for Indias own coronavirus vaccine could boost its public acceptance SECTIONS Last Updated: Mar 04, 2021, 03:18 PM IST Share Synopsis Any boost to the vaccines acceptance in India, which on Thursday reported a new COVID-19 cases at their highest in five weeks, could also brighten its export prospects. Bharat Biotech said 40 countries were interested in COVAXIN. Bharat Biotech Covaxin Efficacy Data: How effective is the vaccine? Indian doctors and politicians on Thursday welcomed e...

Echoing the views of Opposition-ruled states that have questioned the emergency use authorisation given to Bharat Biotechs Covaxin without phase-III trials being completed, Banerjee pointed out that doubts had been expressed about the vaccines as the efficacy data had not been put out in public domain.

MUMBAI: The debate among medical professionals now is which one of the two vaccines granted emergency-use approval would they take, if given a choice. Several doctors, including KEM Hospital dean Dr Hemant Deshmukh, said Covishield, developed by Oxford-AstraZeneca and manufactured by Serum Institute of India, would be their preferred vaccine since Covaxin’s efficacy data is not available yet. Incidentally, KEM was one of the sites where Covishield’s trial was conducted. “The reason is si...

An affiliate of China's state-owned drug maker Sinopharm said on Wednesday its COVID-19 vaccine showed 79.34% efficacy and it has requested regulatory approval of the shot, moving a step closer to become China's first approved vaccine for general public use. The efficacy rate, based on an interim analysis of Phase III clinical trials, is lower than 86% rate for the same vaccine announced by the United Arab Emirates on Dec. 9, based on preliminary data from trials there. There have be...